Fred Brown

1993 and free circulation of vaccines within the E.E.C.

Vypredaná

Fred Brown 1993 and free circulation of vaccines within the E.E.C.

4,3

Proceedings of a symposium / International Symposium on Standardization of the Immunopharmacology of Natural and Synthetic Immunomodulators

Vypredaná

Fred Brown Proceedings of a symposium / International Symposium on Standardization of the Immunopharmacology of Natural and Synthetic Immunomodulators

4,3

International Symposium on Continuous Cell Lines - an International Workshop on Current Issues

Vypredaná

Fred Brown International Symposium on Continuous Cell Lines - an International Workshop on Current Issues

4,3

International Workshop on Poliovirus Attenuation

Vypredaná

Fred Brown International Workshop on Poliovirus Attenuation

4,3

International Meeting on Transmissible Spongiform Encephalopathies

Vypredaná

Fred Brown International Meeting on Transmissible Spongiform Encephalopathies

4,3

Virological safety aspects of plasma derivatives

Vypredaná

Fred Brown Virological safety aspects of plasma derivatives

4,3

Recombinant vectors in vaccine development

Vypredaná

Fred Brown Recombinant vectors in vaccine development

4,3

Genetic stability and recombinant product consistency

Vypredaná

Fred Brown Genetic stability and recombinant product consistency

4,3

Replacement, reduction and refinement of animal experiments in the development and control of biological products

Vypredaná

Fred Brown Replacement, reduction and refinement of animal experiments in the development and control of biological products

4,3

New Approaches to stabilisation of vaccines potency

Vypredaná

Fred Brown New Approaches to stabilisation of vaccines potency

4,3

Viral safety and evaluation of viral clearance from biopharmaceutical products

Vypredaná

Fred Brown Viral safety and evaluation of viral clearance from biopharmaceutical products

4,3

Development of specifications for biotechnology pharmaceutical products

Vypredaná

Fred Brown Development of specifications for biotechnology pharmaceutical products

4,3